MedTrace Logo

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

NCT06500884 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to better characterize the signs or symptoms of talquetamab-related taste changes and to better characterize the signs or symptoms of ramantamig-related taste changes.

Conditions

Interventions

DRUG

Talquetamab

Talquetamab will be administered subcutaneously.

DRUG

Prophylaxis A

Prophylaxis A will be administered orally.

DRUG

Prophylaxis B

Prophylaxis B will be administered orally.

DRUG

Prophylaxis C

Prophylaxis C will be administered orally.

DRUG

Prophylaxis D

Prophylaxis D will be administered topically.

DRUG

Ramantamig

Ramantamig will be administered subcutaneously.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-26
Primary Completion
2030-05-30
Completion
2030-05-30
FDA Drug
Yes

Countries

  • United States
  • Brazil
  • Netherlands
  • Puerto Rico
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06500884 on ClinicalTrials.gov